SenesTech Inc (NASDAQ:SNES) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokers have set a 12 month consensus target price of $2.50 for the company and are anticipating that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also assigned SenesTech an industry rank of 180 out of 255 based on the ratings given to related companies.
SNES has been the subject of several research analyst reports. ValuEngine raised SenesTech from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Zacks Investment Research raised SenesTech from a “sell” rating to a “hold” rating in a research note on Wednesday, July 25th.
Shares of NASDAQ SNES traded down $0.02 during mid-day trading on Thursday, hitting $0.70. The company had a trading volume of 171,347 shares, compared to its average volume of 336,637. SenesTech has a 1 year low of $0.30 and a 1 year high of $3.87. The company has a current ratio of 5.05, a quick ratio of 4.07 and a debt-to-equity ratio of 0.05.
SenesTech (NASDAQ:SNES) last posted its quarterly earnings data on Monday, August 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.12). The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.40 million. SenesTech had a negative net margin of 13,362.22% and a negative return on equity of 214.75%. sell-side analysts forecast that SenesTech will post -0.61 earnings per share for the current fiscal year.
SenesTech Company Profile
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Read More: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.